DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Topiramate Trial for Compulsive Buying

Information source: University of Sao Paulo
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Compulsive Shopping

Intervention: Topiramate (Drug); placebo (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: University of Sao Paulo

Official(s) and/or principal investigator(s):
Hermano Tavares, Professor, Principal Investigator, Affiliation: associate

Overall contact:
Hermano Tavares, Professor, Phone: +55-11-26617805, Email: hermanot@uol.com.br


It is a double blind controlled study to test the hypothesis that Topiramate is more effective than placebo in the treatment of compulsive buying, during a period of 12 weeks

Clinical Details

Official title: Double Blind Controlled Trial of Topiramate for Compulsive Buying

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Yale-Brown Compulsive-Obsessive Scale Shopping Version

Secondary outcome:

Clinical Global Impression scale (CGI)

Udvalg for KliniskeUndersøgelser Side Effect Rating Scale (UKU)

Detailed description: Compulsive buying is a prevalent disorder with no approved pharmacological treatment. Previous reports suggest that topiramate could be useful in reducing impulsivity in pathological gambling and other impulse control disorders, as well as craving in substance addictions. The goal of this study was to investigate the effectiveness of topiramate combined with brief cognitive restructuring in treating compulsive buying, compared with just cognitive restructuring treatment+placebo.


Minimum age: 21 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Match criteria for compulsive buying, according to McElroy et al. (1994), confirmed

by semi-structured interview modeled after the Schedules for clinical assessment in neuropsychiatry (SCID)

- woman within fertility age have to be already practicing an acceptable contraception

method and to be negative at a pregnancy test Exclusion Criteria:

- illiteracy

- pregnancy and breastfeeding for woman

- previous history of alcohol abuse/dependence with current elevation of liver enzymes,

or a present diagnosis of alcohol abuse/dependence

- past or current drug abuse/dependence, except for nicotine

- history of current or past Fifth Edition of the Diagnostic and Statistical Manual of

Mental Disorders diagnosis of bipolar disorder, schizophrenia, psychosis or any neuropsychiatric condition causing cognitive impairment

- a history of suicide attempt or acute suicide risk

- severe depression indicated by a score higher than 30 at the beck depression


- current participation on psychotherapy or use of pharmacological agent or

experimental dispositive for compulsive buying in the past 3 months

- current use of psychotropic drugs, except benzodiazepines

- cardiovascular disease including a history of heart attack, stroke, arrhythmia,

cardiac failure in the past 5 years. Uncontrolled high blood pressure.

- chronic or acute renal or liver failure, as well as Retinopathy and thyroidopathy

- a personal or family history of nephrolithiasis

- immunodeficiency

- any blood dyscrasia

- contraindication or allergy to topiramate

- history of seizures

- dont't have a phone number for contact

- live alone and don't have a person that can inform about the shopping behavior

Locations and Contacts

Hermano Tavares, Professor, Phone: +55-11-26617805, Email: hermanot@uol.com.br

Associação Viver Bem, São Paulo, SP 05404-010, Brazil; Not yet recruiting
Hermano Tavares, Professor, Principal Investigator
Additional Information


Starting date: January 2015
Last updated: May 12, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017